Methods, devices and systems for capturing biomarkers are provided. In particular, methods, compositions, and systems that utilize affinity capture devices comprising a processing chamber, affinity capture agent and porous membrane are provided.

Antibodies and antigen binding fragments that bind to neublastin polypeptides are disclosed. Also disclosed are methods of using the antibodies and antigen binding fragments in assays for detecting the presence or amount of endogenous and/or exogenous neublastin in a sample and in methods of antagonizing neublastin bioactivity.

The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.

A method of determining and evaluating quality of peanut raw material suitable for processing protein. The method includes the following step: determining fruit shape score, total protein content, leucine content, arginine content, conarachin I content and the mass percentage of the subunit with molecular weight of 23.5 kDa to total protein in the peanut sample to be tested; putting the determined values into formula (1) to obtain the protein powder quality of the peanut sample. The disclosure reduces the analysis step. The disclosure establishes the model of evaluating raw material quality for peanut protein processing, and the peanut protein powder quality can be determined by 6 peanut quality characteristics. The determination of indexes in the model can be predicted by the near infrared analyzer. Through the near infrared analysis of peanut kernel, the indexes in the model can be simultaneously predicted without any damage to the peanut kernel.

Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample.

The disclosure provides an ABD binding polypeptide comprising an ABD binding motif BM, which motif consists of an amino acid sequence selected from EX.sub.2X.sub.3X.sub.4AX.sub.6X.sub.7EIX.sub.10X.sub.11LPNLX.sub.16X.sub.17X.sub.18QX.sub.20X.sub.21AFIX.sub.25X.sub.26LX.sub.28D (SEQ ID NO: 166) and amino acid sequences with at least 89 % identity thereto.

The present disclosure relates to a diagnostic kit capable of accurately diagnosing diseases or disorders related with abnormal aggregation or misfolding of proteins, including disorders or diseases caused by aggregation of -amyloid such as Alzheimer's disease as well as disorders or diseases caused by aggregation of other proteins, based on concentration analysis of the aggregated proteins before and after dissociation.

Methods for improving immunoassays, and in particular, assays for B-Type natriuretic peptide analogues resistant to prolyl-specific dipeptidyl degradation are provided wherein one or more antibodies are selected such that the one or more antibodies detect a biologically active form of a natriuretic peptide of interest.

Described herein are methods for identifying signature peptides for quantifying a polypeptide of interest in a sample. The methods include cleaving the polypeptide into peptides; detecting a multiplicity of the peptides with a quantitative analytical instrument; comparing the linearity of signals attributable to pairs of the peptides in a multiplicity of samples; and selecting signature peptides from a group of peptides with more highly correlated signals.

The present disclosure relates to an in vitro method for diagnosing Alzheimer's disease (AD), comprising the steps of: a) determining the content of mercaptoalbumin (HMA) in a sample of cerebrospinal fluid (CSF); and b) comparing the content determined with the content of HMA in CSF in healthy subjects. If the HMA content is less than that of the healthy subjects, it is indicative of AD.